5 Amino 1MQ vs AOD 9604: Metabolic Compounds Compared

Almost every write-up on 5 amino 1mq vs aod 9604 makes the same mistake in its opening line: it calls both of them peptides. Only one is. AOD-9604 is a 16-residue fragment of human growth hormone weighing roughly 1,800 daltons. 5-Amino-1MQ is a synthetic quinolinium compound under 200 daltons, structurally closer to a benchtop reagent than to anything else sitting in a peptide freezer.

Our team fields this question from research buyers more than any other in the metabolic category. Both compounds occupy the same catalogue aisle, which creates the illusion that they're interchangeable choices for the same experiment. They aren't, and the reason has nothing to do with potency.

What is the difference between 5 amino 1mq vs aod 9604?

5-Amino-1MQ is an orally active small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), studied in rodent models of diet-induced obesity. AOD-9604 is a peptide corresponding to residues 176 to 191 of human growth hormone, investigated for lipolytic activity in adipose tissue. One blocks an intracellular enzyme. The other mimics a hormone region.

The over-simplification worth discarding is that both compounds simply 'burn fat'. They act at different levels of biology entirely: 5-Amino-1MQ alters methyl-group accounting inside the adipocyte, while AOD-9604 reproduces the lipolytic C-terminal region of growth hormone without the IGF-1 signalling attributed to the intact hormone. What follows covers mechanism and molecular class, route of delivery in published work, the honest state of the evidence behind each, and how both sit next to MOTS-c, Lipo-C and tesofensine.

Two molecules working at completely different levels of biology

NNMT, the target of 5-Amino-1MQ, methylates nicotinamide using SAM (S-adenosyl-L-methionine) as the methyl donor. That single reaction consumes two things the cell values: a precursor that would otherwise feed the NAD+ salvage pathway, and a unit of cellular methylation capacity. NNMT is expressed heavily in adipose tissue and liver, which is why inhibiting it became an obesity research target at all. Work published in Biochemical Pharmacology by Neelakantan and colleagues reported that membrane-permeable small-molecule NNMT inhibitors reduced fat mass in high-fat-diet mice, and the compound has been studied in rodent models since.

AOD-9604 works nowhere near that pathway. It's the C-terminal lipolytic region of human growth hormone, developed originally by Metabolic Pharmaceuticals, and animal research has reported stimulation of lipolysis and reduced lipogenesis without the IGF-1 elevation or glucose disturbance associated with the full hormone. That selectivity was the entire premise of the molecule.

One practical marker of how different these are: AOD-9604 is listed by the World Anti-Doping Agency under growth hormone fragments in the prohibited S2 class. 5-Amino-1MQ is a small molecule with no hormone analogue status at all. Both are supplied by us as 5-Amino-1MQ and AOD-9604 for laboratory research only, and neither is an approved drug.

The methyl-donor detail that most comparisons skip entirely

Here's the nuance that changes how a study gets designed. NNMT inhibition is not a fat-burning mechanism in any direct sense. It's a methyl-group accounting change. Blocking the enzyme is reported to spare SAM and increase the nicotinamide pool available to NAD+ salvage, and the downstream metabolic effect is a consequence of that shift, not of any receptor activation.

Which means the effect size is expression-dependent, not just dose-dependent. In a model where adipose NNMT expression is low, inhibiting the enzyme has little to act on. This is the single most common reason 5-Amino-1MQ results in lean animal models look unimpressive next to results in diet-induced obese models, and it's why comparing the compound head-to-head with a hormone fragment on a flat dose-response basis produces misleading conclusions. In our experience supplying research labs, this is where study design goes wrong far more often than material quality does.

The route difference follows directly from molecular class. 5-Amino-1MQ is membrane-permeable and has been administered orally in preclinical work. AOD-9604 is a peptide, so gastric proteases cleave it, and published research has overwhelmingly used parenteral delivery. That single fact reshapes any model requiring oral gavage.

And the evidence gap deserves a straight statement: AOD-9604's human obesity development programme did not produce the separation from placebo its developer needed, and the obesity programme was discontinued. That result is part of the record and belongs in any honest aod 9604 vs 5 amino 1mq assessment.

Where MOTS-c, Lipo-C and tesofensine sit alongside these two

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene, described by Lee and colleagues in Cell Metabolism, and research reports that it activates AMPK (AMP-activated protein kinase) and acts through the folate and methionine one-carbon cycle. That makes 5 amino 1mq vs mots c a genuinely interesting pairing rather than a category error: both intersect one-carbon metabolism, MOTS-c through the folate cycle and 5-Amino-1MQ through SAM consumption. Route separates them again, since MOTS-c is a peptide requiring parenteral delivery in published work.

Lipo-C is a different animal completely. It's a compounded lipotropic blend, typically methionine, inositol and choline, often with cyanocobalamin. It has no enzyme target and no receptor. So the lipo c vs 5 amino 1mq question is really a comparison between a nutrient cocktail and an enzyme inhibitor, and the two aren't measuring the same thing. You can view our Lipo-C and tesofensine listings alongside the wider metabolic research catalogue.

Tesofensine is a triple monoamine reuptake inhibitor acting on serotonin, noradrenaline and dopamine, originally developed by NeuroSearch for neurodegenerative indications before being studied in obesity. So 5 amino 1mq vs tesofensine contrasts a peripheral enzyme target with a central nervous system appetite mechanism.

One compliance point worth stating plainly: everything described here is published laboratory research on research-use-only materials, none of which are FDA-approved drugs for human or animal use. If your interest stems from an animal health question, talk to your veterinarian rather than sourcing research compounds.

5 Amino 1MQ vs AOD 9604: full comparison against the metabolic category

This table maps the five compounds researchers most often evaluate against each other, across the four variables that actually determine study feasibility: molecular class, mechanism, route and evidence depth.

What If: Research Sourcing and Design Scenarios

What if the study model requires oral delivery rather than injection?

Narrow the shortlist to the small molecules before anything else. 5-Amino-1MQ has been administered orally in rodent work because it is membrane-permeable and not protease-sensitive, and tesofensine is orally active in its published human studies. AOD-9604 and MOTS-c are peptides, and oral delivery of either requires formulation work that most labs won't have budgeted for. Choosing a peptide first and solving delivery second is how a study timeline doubles.

What if a lab wants to run 5-Amino-1MQ and MOTS-c in the same model?

Document the one-carbon overlap in the study design before dosing anything. MOTS-c research points to the folate and methionine cycle, and 5-Amino-1MQ acts on SAM consumption through NNMT, so both compounds touch methyl metabolism from different entry points. Running them concurrently without accounting for that overlap makes any observed effect difficult to attribute. Separate arms, with a methyl-donor control, produce cleaner data than a combined arm.

What if peptide material arrives warm after shipping?

Quarantine the vial and check the supplier's handling documentation rather than assuming the material is fine because it looks fine. Lyophilised peptides are generally held at minus 20 degrees Celsius before reconstitution, and once in solution most suppliers specify 2 to 8 degrees Celsius with limited working life. Protein denaturation from a temperature excursion is not visible and cannot be assessed by eye. A certificate of analysis tells you what shipped, not what survived transit.

The unglamorous truth about comparing metabolic research compounds

Here's the honest answer: the 5 amino 1mq vs aod 9604 debate is mostly settled by evidence quality, not by mechanism elegance. 5-Amino-1MQ has a coherent preclinical rationale and very little human data. AOD-9604 has a coherent mechanism and a human obesity programme that didn't deliver. Search aod9604 reddit or aod9604 peptide reddit and you'll find the same pattern repeatedly: self-reported anecdote presented with the confidence of trial data, usually with no mention of the discontinued development programme. Anecdote is not an evidence base. Treat both compounds as open research questions, because that is exactly what they are.

The deeper point in any 5 amino 1mq vs aod 9604 comparison is that these two compounds were never really competitors. One came out of hormone fragment research in the 1990s and 2000s; the other came out of enzyme inhibitor screening built on NAD+ and methylation biology that only matured in the last decade. They ended up on the same product page because of how supplier catalogues are organised, not because of how the science developed. If you're choosing between them, choose on the mechanism your model can actually measure, and read the certificate before you read the forum thread.